Trimebutine, a new antispasmodic in the treatment of dyspepsia
Walters, J.M.; Crean, P.; Mccarthy, C.F.
Irish Medical Journal 73(10): 380-381
1980
ISSN/ISBN: 0332-3102 PMID: 7429788 Document Number: 155642
In a double-blind cross-over study, 24 patients with X-ray and endoscopically negative dyspepsia were treated with the antispasmodic trimebutine 200 mg 3 times daily and placebo, each for a consecutive period of 4 wk. The effect of each treatment upon individual symptoms was noted and patient treatment preference recorded on completion of the trial. No overall significant difference between trimebutine and placebo was found, though there was a significant symptomatic improvement in patients who received trimebutine as their 2nd treatment (10/12) compared with placebo (P = 0.038). No evidence of clinical or biochemical toxicity was observed.